<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424264</url>
  </required_header>
  <id_info>
    <org_study_id>WRHI061</org_study_id>
    <nct_id>NCT04424264</nct_id>
  </id_info>
  <brief_title>The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants</brief_title>
  <acronym>EpiTAF</acronym>
  <official_title>The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Willem Daniel Francois Venter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Witwatersrand, South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacokinetic study investigating the effect of rifampicin on the
      pharmacokinetics of intracellular tenofovir-diphosphate and plasma tenofovir when
      coadministered with tenofovir alafenamide fumarate during the maintenance phase of
      tuberculosis treatment in TB/HIV-1 coinfected participants (EpiTAF)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, sequential, single centre pharmacokinetic (PK) study investigating the
      effect of rifampicin on the pharmacokinetics of intracellular tenofovir-diphosphate and
      plasma tenofovir when coadministered with tenofovir alafenamide fumarate during the
      maintenance phase of tuberculosis treatment in TB/HIV-1 coinfected participants (EpiTAF).

      An open-label, sequential, pharmacokinetic (PK) drug-drug interaction study will be conducted
      in medically stable virologically suppressed HIV-1 infected adults coinfected with TB, who
      are in the maintenance phase of their TB treatment. After intensive PK evaluation of IC
      TFV-DP and pTFV, participants will be switched from their standard-of-care tenofovir
      disoproxil fumarate (TDF)/FTC/EFV regimen, to TAF + 3TC + EFV at the start of the study
      treatment period. After 28 days each participant will have intensive PK evaluation of IC
      TFV-DP and pTFV on TAF + 3TC + EFV with rifampicin (RIF). After the second intensive PK
      assessment is completed, participants will be switched back to TDF/FTC/EFV, with a final
      intensive PK evaluation of IC TFV-DP and pTFV 8 days after completion of TB treatment, at the
      final study visit. Eighteen volunteers will be enrolled for a target of 13 participants
      completing the study.

      The study includes screening and enrolment visits, 1 visit on day 28 and an end of study
      visit 28 days after the end of TB treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IC TFV-DP concentrations during coadministration of TAF or TDF with RIF/INH in TB/HIV-1 coinfected participants</measure>
    <time_frame>56 days</time_frame>
    <description>Intracellular and plasma TFV-DP concentrations measured during coadministration of TAF or TDF with RIF/INH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of irological suppression (HIV-1 RNA &lt; 50 copies/mL)</measure>
    <time_frame>At screening, day 28, completion of TB and EOS visits</time_frame>
    <description>Assessment of maintenance of virological suppression (HIV-1 RNA &lt; 50 copies/mL) while on TAF/RIF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison plasma concentrations of TAF with TDF</measure>
    <time_frame>56 days</time_frame>
    <description>Assessment to compare the plasma concentrations of tenofovir of TAF with TDF during coadministration of RIF/INH in TB/HIV-1 coinfected participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of IC TFV-DP concentrations of TDF</measure>
    <time_frame>56 days</time_frame>
    <description>4. To compare the IC TFV-DP concentrations of TDF with and without coadministration with RIF/INH in TB/HIV-1 coinfected participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAF 25 mg once-daily administered with RIF/INH 600*/300mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid</intervention_name>
    <description>TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600*/300 mg daily from screening until enrolment (days -15 to 0)</description>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
    <other_name>Atripla</other_name>
    <other_name>Rifinah</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid</intervention_name>
    <description>TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/*300 mg daily (days 1 to ≤ 56)</description>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
    <other_name>HepBest</other_name>
    <other_name>Stocrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz</intervention_name>
    <description>TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg &lt;70kg, 750mg &gt;70kg</description>
    <arm_group_label>Tenofovir Alafenamide</arm_group_label>
    <other_name>Atripla</other_name>
    <other_name>Rifinah</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (≥ 18 years old) male or female

          2. HIV-1 infected on TDF/FTC/EFV with HIV RNA &lt; 50 copies/mL in the last three months

          3. On TB treatment in the maintenance phase (RIF/INH) with at least one month of TB
             treatment needed for completion

          4. Women of childbearing potential must not be pregnant or breastfeeding, with a negative
             pregnancy test at screening

          5. Women must be postmenopausal, surgically sterile or practicing an effective birth
             control method (established before and maintained throughout the trial). Women who are
             not sexually active must agree to use an effective birth control method if they become
             heterosexually active during the trial

          6. Understand the purpose of and procedures required for the study and having confirmed
             they are willing to participate in the study by signing the informed consent document.

        Exclusion Criteria:

          1. Weight &lt; 40 kg

          2. Estimated creatinine clearance &lt; 50 mL/min

          3. Any active clinically significant or life-threatening disease (e.g. acute infections,
             pancreatitis, hepatitis, cardiac dysfunction), medical or psychiatric condition, or
             findings during screening, that in the investigator's opinion would compromise the
             safety of the participant or the study outcome, or their ability to comply with the
             study procedures

          4. Chronic medical requirement for any drugs that are known to affect the PK of the study
             drugs

          5. Active drug/alcohol abuser

          6. History of allergy or hypersensivity to any of the study drugs

          7. Currently enrolled in an investigational drug study or has participated in an
             investigational drug study within the 4 weeks before screening

          8. Unable to comply with study protocol and study protocol restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simiso Sokhela, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (Wits RHI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nomathemba Chandiwana, MBBCh</last_name>
    <phone>+2711358 5651</phone>
    <email>nchandiwana@wrhi.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Godspower Akpomiemie, MPH</last_name>
    <phone>+2711358 5370</phone>
    <email>gakpomiemie@wrhi.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <phone>+27113585500</phone>
      <email>ssokhela@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Nonkululeko Mashabane, BPharm</last_name>
      <phone>+27113585543</phone>
      <email>nmashabane@wrhi.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nomathemba Chandiwana, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wits RHI Yeoville Clinic</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <phone>+27113585500</phone>
      <email>ssokhela@wrhi.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Nonkululeko Mashabane, BPharm</last_name>
      <phone>+27113585543</phone>
      <email>nmashabane@wrhi.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>Simiso Sokhela, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nomathemba Chandiwana, MBBCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Witwatersrand, South Africa</investigator_affiliation>
    <investigator_full_name>Willem Daniel Francois Venter</investigator_full_name>
    <investigator_title>Divisional Director of Ezintsha</investigator_title>
  </responsible_party>
  <keyword>Rifampicin, RIF/INH</keyword>
  <keyword>Tenofovir alafenamide fumarate (TAF)</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Intracellular tenofovir-diphosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

